Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma
Launched by SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE · Oct 8, 2016
Trial Information
Current as of July 21, 2025
Unknown status
Keywords
ClinConnect Summary
Non-Small-Cell Lung Cancer(NSCLC)is one of the malignancies with high incidence and mortality. Epidermal growth factor receptor (EGFR) is implicated in NSCLC pathogenesis. Certain patient subgroups with NSCLC (ie, women, never-smokers, East Asians,adenocarcinoma) have higher rates of EGFR mutations, rendering them more responsive to EGFR tyrosine kinase inhibitors (TKIs; eg, gefitinib, erlotinib, Icotinib). Among patients with advanced EGFR-mutated NSCLC, treatment with EGFR-TKIs is associated with response rates of 56 to 74% and a median progression-free survival(mPFS) of 10 to 14 months;b...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Pathologically or cytologically confirmed stage IIIa-IV pulmonary adenocarcinoma;
- • With activating EGFR mutation (either exon19del or exon21L858R) and one month of gefitinib as first-line or second-line therapy without disease progression (PD);
- • With TCM diagnostic pattern Qin-and-yin dificiency;
- • Age ≥18 years old;
- • Estimated life expectancy of at least 12 weeks;
- • Without major organ dysfunction: hemoglobin ≥9 g/dL, absolute neutrophil count (ANC) ≥1.5\*109/L, platelets ≥100 \*109/L,bilirubin ≤1.5ULN, alkaline phosphatase (AP), aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 upper limited number(ULN) (AP, AST, ALT ≤5ULN is acceptable with liver metastasis).INR≤1.5, APTT in the normal range( 1.2DLN-1.2ULN),creatinine ≤1.5ULN;
- Exclusion Criteria:
- • with other malignant tumor except NSCLC 5 years previous to study entry;
- • PD after onee month of gefitinib treatment
- • Estimated life expectancy less than 12 weeks;
- • Brain metastasis with relevant symptoms
- • History of cardiovascular disease: Congestive Heart Failure \> grade II in NYHA.Unstable angina patients (have angina symptoms in rest) or a new occurrence of angina (began in the last 3 months) or myocardial infarction happens in the last 6 months;
- • Pregnant or child breast feeding women;
- • Mental or cognitive disorders;
About Shanghai University Of Traditional Chinese Medicine
Shanghai University of Traditional Chinese Medicine is a leading institution dedicated to advancing the field of traditional Chinese medicine through rigorous research and innovative clinical practices. With a strong emphasis on integrating traditional methodologies with modern scientific approaches, the university aims to enhance healthcare outcomes and promote holistic wellness. As a sponsor of clinical trials, it is committed to exploring the efficacy and safety of traditional therapies, contributing to evidence-based practices, and fostering collaborations that bridge Eastern and Western medical paradigms. The university's focus on education, research, and community engagement positions it as a pivotal player in the global health landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials